Viewing Study NCT06413992


Ignite Creation Date: 2025-12-24 @ 3:49 PM
Ignite Modification Date: 2026-01-03 @ 6:04 AM
Study NCT ID: NCT06413992
Status: RECRUITING
Last Update Posted: 2024-05-14
First Post: 2024-04-23
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module